The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase

被引:165
作者
Cooper, CE
Lynagh, GR
Hoyes, KP
Hider, RC
Cammack, R
Porter, JB
机构
[1] UCL, SCH MED, DEPT HAEMATOL, LONDON WC1E 6HX, ENGLAND
[2] UNIV LONDON KINGS COLL, DIV LIFE SCI, MET BIOL & MED CTR, LONDON W8 7AH, ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1074/jbc.271.34.20291
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The depletion of cellular iron can lead to the inhibition of ribonucleotide reductase, preventing new DNA synthesis and hence inhibiting cell proliferation. Electron paramagnetic resonance (EPR) spectroscopy has been used to examine simultaneously for the first time the relationship between chelation of intracellular iron and the rate of removal and regeneration of the tyrosyl radical of ribonucleotide reductase within intact human leukemia K562 cells. The different physiochemical characteristics of relatively hydrophobic low molecular weight bidentate hydroxypyridinone chelators and the higher molecular weight hexadentate ferrioxamine have been exploited to elucidate these interactions further. The base-line concentration of EPR detectable mononuclear nonheme iron complexes was 3.15 +/- 1.05 mu M, rising on incubation with chelators more rapidly with hydroxypyridinones than with desferrioxamine. Hydroxypyridinones also removed the tyrosyl radical more rapidly, apparently as a consequence of depletion of the intracellular iron pools necessary to regenerate the active enzyme and compatible with their reportedly greater cell toxicity. The radical decay rate is consistent with previous models, suggesting that iron is spontaneously removed from mammalian ribonucleotide reductase. Upon removal of extracellular chelator the regeneration of the tyrosyl radical was significantly faster for hydroxypyridinones than for desferrioxamine, consistent with their differential effects on cell cycle synchronization.
引用
收藏
页码:20291 / 20299
页数:9
相关论文
共 40 条
  • [1] ATKIN CL, 1973, J BIOL CHEM, V248, P7464
  • [2] IMPAIRMENT OF NUCLEOTIDE-METABOLISM BY IRON-CHELATING DEFEROXAMINE
    BARANKIEWICZ, J
    COHEN, A
    [J]. BIOCHEMICAL PHARMACOLOGY, 1987, 36 (14) : 2343 - 2347
  • [3] SPECTRUM AND IRON CONTENT OF PROTEIN B2 FROM RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE
    BROWN, NC
    ELIASSON, R
    REICHARD, P
    THELANDER, L
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1969, 9 (04): : 512 - +
  • [4] CAMMACK R, 1988, METHOD ENZYMOL, V167, P427
  • [5] ELECTRON-PARAMAGNETIC-RESONANCE SPECTROSCOPY OF IRON COMPLEXES AND IRON-CONTAINING PROTEINS
    CAMMACK, R
    COOPER, CE
    [J]. METALLOBIOCHEMISTRY, PT D: PHYSICAL AND SPECTROSCOPIC METHODS FOR PROBING METAL ION ENVIRONMENTS IN METALLOPROTEINS, 1993, 227 : 353 - 384
  • [6] CHITAMBAR CR, 1988, BLOOD, V72, P1930
  • [7] COOPER CE, 1994, FREE RADICAL DAMAGE, P65
  • [8] SYNTHESIS, PHYSICOCHEMICAL PROPERTIES, AND BIOLOGICAL EVALUATION OF N-SUBSTITUTED 2-ALKYL-3-HYDROXY-4(1H)-PYRIDINONES - ORALLY-ACTIVE IRON CHELATORS WITH CLINICAL POTENTIAL
    DOBBIN, PS
    HIDER, RC
    HALL, AD
    TAYLOR, PD
    SARPONG, P
    PORTER, JB
    XIAO, GY
    VANDERHELM, D
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (17) : 2448 - 2458
  • [9] ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114
  • [10] ERIKSSON S, 1984, J BIOL CHEM, V259, P1695